BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Accelerating mRNA Drug Substance Process Scale Up and Manufact
 uring\n\nBuilt with biopharmaceutical industry insights\, this in-person 
 conference will bring together key opinion leaders to delve deep into the
  key remaining challenges associated with mRNA process scale up and manuf
 acturing towards regulatory harmonization by optimizing in vitro transcri
 ption\, purification and analytical validation mRNA drug substance.\n\nWi
 th 200+ attendees from large pharma\, innovative biotech and KOLs of acad
 emia who are ready to discuss how the future mRNA process development and
  manufacturing is shaping in accordance with regulatory expectations and 
 emerging tools and technologies to support the development of scalable an
 d commercially viable mRNA-based therapeutics and vaccines\, join us in B
 oston to hear how they address the major challenges facing the industry.\
 n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1170386-2?pid=185Brochure:&nb
 sp\;https://go.evvnt.com/1170386-3?pid=185\n\nPrices:Drug Developer - Con
 ference + 2 Workshops: USD 4097.00\,Drug Developer - Conference + 1 Works
 hop: USD 3498.00\,Drug Developer - Conference Only: USD 2899.00\,Academic
  - Conference + 2 Workshops: USD 3497.00\,Academic - Conference + 1 Works
 hop: USD 2998.00\,Academic - Conference Only: USD 2499.00\,Service Provid
 er - Conference + 2 Workshops: USD 4897.00\,Service Provider - Conference
  + 1 Workshop: USD 4198.00\,Service Provider - Conference Only: USD 3499.
 00\n\nSpeakers:&nbsp\;Ales Stancar\, Managing Director\, BIA Separations\
 , Andreas Kuhn\, SVP - RNA Biochemistry and Manufacturing\, BioNTech SE\,
  Camilla Foged\, Professor - Vaccine Design and Delivery\, University of 
 Copenhagen\, Christopher Kelly\, Director - Regulatory Affairs CMC\, Mode
 rna\, Craig Martin\, Professor - Chemistry\, University of Massachusetts 
 Amherst\, David Cirelli\, Senior Director - Analytical Research and Devel
 opment\, Pfizer\, Dushyant Varshney\, CTO\, Arcturus Therapeutics\, Elain
 e Peters\, Director - Cell and Gene Therapy Analytical Capabilities\, Gen
 entech\, Elvan Cavac\, Scientist II - mRNA Upstream Process Development\,
  Tessera Therapeutics\, Emily English\, Senior Director - Quality\, Carte
 sian Therapeutics\, Gautam Sanyal\, Principal Consultant\, Vaccine Analyt
 ics LLC\, Harris Makatsoris\, Professor - Sustainable Manufacturing Syste
 ms\, King's College London\, Hiroshi Abe\, Professor\, Nagoya University\
 , Hirra Hussain\, Senior Scientist\, CPI\, Hunter Stitik\, Director - Ent
 erprise Science and Innovation\, ThermoFisher Scientific\, Jin Zhou\, Exe
 cutive Director - Process Development\; mRNA and Protein Biologics\, Ultr
 agenyx Pharmaceutical\, Khaled Yamout\, Senior Director\, Manufacturing a
 nd Quality Control\, TriLink BioTechnologies\, Kristie Bloom\, Researcher
 \, University of the Witwatersrand\, Madelyn Johnstone- Robertson\, BioPr
 ocess Engineer\, Afrigen Biologics\, Mark McElligott\, Owner/Principal En
 gineer\, BioX\, Martin Carvalho\, Head - Quality\, mRNA Centre of Excelle
 nce\, Sanofi\, Petro Terblanche\, Managing Director\, Afrigen Biologics\,
  Philippe Alexandre Gilbert\, Senior Program Officer - CMC\, Bill and Mel
 inda Gates Foundation\, Rachit Jain\, Director - Process Development\, Te
 ssera Therapeutics\, Scott Alderucci\, Director - Process Development\, C
 uria\, Serena Smith\, Director - Strategy and Market Intelligence\, Therm
 o Fisher Scientific\, Shefal Parikh\, Director - mRNA Process Development
 \, Beam Therapeutics\, So-ching\, Brazer Senior Director - Global Regulat
 ory Affairs CMC\, Ultragenyx Pharmaceutical\, Srinivasulu Bandi\, Directo
 r - BioProcess Development\, Senda Biosciences\, Steve Pascolo\, Professo
 r\, University Hospital of Zürich\, Thomas Aune\, Professor\, Vanderbilt 
 University Medical Center\, Thomas Nsenda\, Director Business Development
  EMEA\, Pfanstiehl\, Vijay Dhawan\, Head - Analytical Development/QC\, Ge
 nomic Medicine\, Sanofi\, Xinyue Zhang\, Investigator - mRNA Process and 
 Analytical Development\, GeneLeap Biotech\, Zheng Meng\, Senior Director 
 - Analytical Development\, Ultragenyx Pharmaceutical\n
DTEND:20220922T170000
DTSTAMP:20260515T080412Z
DTSTART:20220920T090000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Suffolk Co
 unty\, 02115\,
SEQUENCE:0
SUMMARY:Accelerating mRNA Drug Substance Process Scale Up and Manufacturin
 g\nBuilt with biopharmaceutical industry insights\, this in-person confer
 ence will...
UID:ddb49bb8-44f4-498c-96a8-b9378290b023
END:VEVENT
END:VCALENDAR